Lattice Biologics Ltd.
Lattice Biologics Ltd. is an emerging leader in cellular therapies and tissue engineering, producing ECM-based allograft technology and amniotic fluid supplements for joint pain treatment.
Classification
Profile
Funding
Funding details not yet available.
Fundraising & market
Provides minimally processed amniotic fluid supplements like AmnioVisc for osteoarthritis and next-generation ECM-based allografts for tissue engineering.
Patients suffering from joint pain and osteoarthritis, and healthcare providers utilizing cellular therapies and tissue engineering solutions.
Direct sales of proprietary biologics products, specifically AmnioVisc and allograft technologies, following debt restructuring to fund production.
Direct commercialization of medical supplements and biologics, leveraging company announcements to drive adoption of new product lines.
Information insufficient.
Production scaling of AmnioVisc and R&D for next-generation ECM-based allograft technology, supported by capital from debt extinguishment.
Proprietary minimally processed amniotic fluid technology, next-generation ECM-based allograft IP, and increased production capacity.
Processing amniotic fluid into supplements, developing ECM-based allografts, managing production scaling, and executing financial restructuring.
Information insufficient.
Operates in the cellular therapy and tissue engineering sector as an emerging leader, differentiating through 100% natural, minimally processed products.
Addresses joint pain associated with osteoarthritis and the need for effective, natural tissue engineering solutions in cellular therapies.
- Regulatory Reinforcement - Prioritize FDA clearance for each indication, retire any unapproved marketing claims, and implement a complian
Regulatory compliance is the linchpin; resolving the FDA issue will unlock broader payer reimbursement and hospital formulary inclusion · Partnership leverage (Cryoport, OA Centers) should be deepened into joint-go-to-market programs, reducing distribution costs and acceleratin · Scaling the product portfolio into cell-based and bio-active formulat
- Regulatory risk is real - The FDA issued a warning letter in Aug 2020 for unapproved COVID-19 claims, highlighting the need for tighter c
Team details not yet available.
No investors recorded yet.